Drugs / GSK376501
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00615212 | Jan → Feb 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00605449 | Jan → Mar 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00495014 | Jun → Dec 2007 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00404963 | Oct 2006 → May 2007 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK376501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00615212 ↗ |
| Known as | GSK-376501A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297386 ↗ |
| Action | Inhibit | “This study is meant to assess potential inhibitory effects of GSK376501 on CYP450 isoenzymes 3A4, 2C8, 2C9.” NCT00615212 ↗ |
| Modality | Small molecule | — CHEMBL4297386 ↗ |
| Route | Oral | “GSK376501 oral tablet” NCT00615212 ↗ |